Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) Clinical Trials

4 clinical trials for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) — RECRUITING · PHASE3
• Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies — RECRUITING · PHASE1
• NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) — RECRUITING · PHASE2
• Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic Leukemia — TERMINATED · PHASE1

Refine this search